To compare the efficacy of antipsychotics (APs) for delirium treatment in patients with cancer, 27 patients treated with 1 of the 4 APs, haloperidol (HPD), risperidone (RIS), olanzapine (OLZ), and quetiapine (QTP), were divided into 2 groups: long half-life (T1/2; HPD, RIS, and OLZ) versus short T1/2 (QTP) or the multiacting receptor-targeted APs (MARTAs; OLZ and QTP) versus the non-MARTA (HPD and RIS). The symptom severity was evaluated by the memorial delirium rating scale (MDAS) on days 0, 3, and 7 following intervention. Significant improvements in total MDAS scores were found in all groups on day 3. However, on day 7, only the short T1/2 group and MARTA group showed significant improvement. Consideration of an AP’s pharmacological properties may be helpful for improving the outcomes of pharmacological delirium intervention in patients with cancer.
BreitbartWAliciY. Agitation and delirium at the end of life: “we couldn’t manage him”. JAMA. 2008;300(24):2898–2910, E2891.
2.
CaraceniANanniOMaltoniM. Impact of delirium on the short term prognosis of advanced cancer patients. Italian Multicenter Study Group on Palliative Care. Cancer. 2000;89(5):1145–1149.
3.
SiddiqiNHouseAOHolmesJD. Occurrence and outcome of delirium in medical in-patients: a systematic literature review. Age Ageing. 2006;35(4):350–364.
4.
Practice guideline for the treatment of patients with delirium. American Psychiatric Association. Am J Psychiatry. 1999;156(5 suppl):1–20.
5.
BreitbartWMarottaRPlattMM. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. Am J Psychiatry. 1996;153(2):231–237.
6.
SeitzDPGillSSvan ZylLT. Antipsychotics in the treatment of delirium: a systematic review. J Clin Psychiatry. 2007;68(1):11–21.
7.
BushSHKanjiSPereiraJL. Treating an established episode of delirium in palliative care: expert opinion and review of the current evidence base with recommendations for future development. J Pain Symptom Manage. 2014;48(2):231–248.
8.
BreitbartWAliciY. Evidence-based treatment of delirium in patients with cancer. J Clin Oncol. 2012;30(11):1206–1214.
9.
SchwartzTLMasandPS. The role of atypical antipsychotics in the treatment of delirium. Psychosomatics. 2002;43(3):171–174.
10.
KhanBAZawahiriMCampbellNL. Delirium in hospitalized patients: implications of current evidence on clinical practice and future avenues for research--a systematic evidence review. J Hosp Med. 2012;7(7):580–589.
11.
HirotaTKishiT. Prophylactic antipsychotic use for postoperative delirium: a systematic review and meta-analysis. J Clin Psychiatry. 2013;74(12):e1136–1144.
12.
MatsuokaYMiyakeYArakakiHTanakaKSaekiTYamawakiS. Clinical utility and validation of the Japanese version of Memorial Delirium Assessment Scale in a psychogeriatric inpatient setting. Gen Hosp Psychiatry. 2001;23(1):36–40.
13.
HattaKKishiYWadaK. Antipsychotics for delirium in the general hospital setting in consecutive 2453 inpatients: a prospective observational study. Int J Geriatr Psychiatry. 2014;29(3):253–262.
SallerCFSalamaAI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (Berl). 1993;112(2-3):285–292.
17.
GardnerDMMurphyALO’DonnellHCentorrinoFBaldessariniRJ. International consensus study of antipsychotic dosing. Am J Psychiatry. 2010;167(6):686–693.
18.
Vella-BrincatJMacleodAD. Haloperidol in palliative care. Palliat Med. 2004;18(3):195–201.
19.
MeagherDJMoranMRajuB. Phenomenology of delirium. Assessment of 100 adult cases using standardised measures. Br J Psychiatry. 2007;190:135–141.
20.
TahirTAMorganEEelesE. NICE guideline: evidence for pharmacological treatment of delirium. J Psychosom Res. 2011;70(2):197–198.
21.
LonerganEBrittonAMLuxenbergJWyllerT. Antipsychotics for delirium. Cochrane Database Syst Rev. 2007;(2):CD005594.
22.
KimSWYooJALeeSY. Risperidone versus olanzapine for the treatment of delirium. Hum Psychopharmacol. 2010;25(4):298–302.
23.
MorganDGMayPCFinchCE. Dopamine and serotonin systems in human and rodent brain: effects of age and neurodegenerative disease. J Am Geriatr Soc. 1987;35(4):334–345.
24.
PalmerAMDeKoskyST. Monoamine neurons in aging and Alzheimer's disease. J Neural Transm Gen Sect. 1993;91(2-3):135–159.
25.
YanaiKWatanabeTMeguroK. Age-dependent decrease in histamine H1 receptor in human brains revealed by PET. Neuroreport. 1992;3(5):433–436.
26.
SasakiYMatsuyamaTInoueS. A prospective, open-label, flexible-dose study of quetiapine in the treatment of delirium. J Clin Psychiatry. 2003;64(11):1316–1321.
27.
HanCSKimYK. A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics. 2004;45(4):297–301.
28.
KimJYJungIKHanC. Antipsychotics and dopamine transporter gene polymorphisms in delirium patients. Psychiatry Clin Neurosci. 2005;59(2):183–188.
29.
LeeKUWonWYLeeHK. Amisulpride versus quetiapine for the treatment of delirium: a randomized, open prospective study. Int Clin Psychopharmacol. 2005;20(6):311–314.
30.
PaeCULeeSJLeeCULeeCPaikIH. A pilot trial of quetiapine for the treatment of patients with delirium. Hum Psychopharmacol. 2004;19(2):125–127.
